Cannabis for Chronic Pain in Australia — Medicinal Options, Evidence & How to Access (2026)

Chronic pain affects approximately 3.6 million Australians — around one in five adults — and costs the national economy an estimated $73 billion per year in healthcare spending and lost productivity. It is the most common indication for medicinal cannabis prescriptions in Australia, accounting for over 60% of all TGA approvals. For many patients, it arrives after years of inadequate pain control from conventional medications, and often after the risks of those medications — particularly opioids — have become unacceptable.

Cannabis has a unique ability to address multiple pain mechanisms simultaneously: reducing the perception of pain intensity, dampening neuroinflammation, improving sleep quality, and easing the mood disruption that makes chronic pain so debilitating. This is why it can work where other medications have partially failed.

This guide covers the complete picture for Australian chronic pain patients — the science, the evidence, which products work for which conditions, how to dose, and how to navigate the prescription system.

The scale of the problem: chronic pain in Australia

Chronic pain is defined as pain lasting longer than three months. Unlike acute pain — which is a signal of injury or illness and typically resolves — chronic pain often persists beyond tissue healing and becomes a condition in its own right.

In Australia:

• 3.6 million people live with chronic pain — more than the combined number of Australians with diabetes, heart disease and asthma
• Chronic pain is the third largest burden of disease in Australia by cost and disability-adjusted life years
• 30% of people with chronic pain are not in paid work due to their condition
• Conventional treatments (physiotherapy, pharmaceutical pain management, surgery) achieve adequate pain control in only about 50% of chronic pain patients
• Australia has among the highest per-capita opioid prescription rates in the world — and opioid-related harm has increased substantially over the past two decades

Medicinal cannabis does not replace comprehensive pain management. But for the substantial proportion of patients who remain inadequately treated despite conventional care, it represents a meaningful additional option.

How cannabis works for pain: the endocannabinoid system

The body’s endocannabinoid system (ECS) plays a central role in pain modulation at multiple levels of the nervous system — from the peripheral nerve endings that detect tissue damage to the brain regions that determine how much that signal bothers you.

CB1 receptors are concentrated in the brain and spinal cord — the central nervous system. They are particularly dense in regions involved in pain processing: the periaqueductal grey, rostral ventromedial medulla, spinal dorsal horn and limbic system. Activation of CB1 receptors reduces the transmission of pain signals upward through the spinal cord and modifies the emotional and cognitive response to pain in the brain.

CB2 receptors are more prevalent in immune cells, peripheral tissue and to a lesser extent the central nervous system. CB2 activation reduces neuroinflammation — which is now understood to be a major driver of chronic pain, particularly neuropathic pain.

THC acts as a direct agonist at both CB1 and CB2 receptors, producing analgesia through both pathways simultaneously. It also improves the mood, appetite and sleep that chronic pain consistently disrupts — which is part of why its benefit for chronic pain patients is often broader than pure pain score reduction.

CBD does not activate CB1 receptors directly but modulates the ECS through several complementary pathways:

• Inhibits FAAH (the enzyme that breaks down the body’s own endocannabinoids), effectively amplifying natural ECS signalling
• Reduces neuroinflammation via CB2 activation in peripheral tissue and the CNS
• Interacts with TRPV1 receptors (“vanilloid” receptors) directly involved in heat and pain sensation
• Blocks GPR55, a receptor involved in pain sensitisation
• Has direct anti-inflammatory effects at the cellular level comparable to some NSAIDs in animal models

Together, THC and CBD produce pain relief that neither achieves as effectively in isolation — the entourage effect. This is supported by clinical evidence: a 2010 Nabiximols (Sativex, a 1:1 THC:CBD spray) study showed significantly greater pain reduction than either cannabinoid alone in cancer pain.

Types of pain cannabis helps most — and least

Not all chronic pain responds equally to cannabis. The evidence is strongest for certain pain mechanisms.

Neuropathic pain — strongest evidence

Neuropathic pain arises from damage or malfunction of the nervous system itself, rather than from ongoing tissue injury. It produces distinctive burning, shooting, electric-shock, hypersensitivity or “pins and needles” sensations. Common causes include:

• Diabetic peripheral neuropathy
• Post-herpetic neuralgia (shingles nerve damage)
• Chemotherapy-induced peripheral neuropathy
• Multiple sclerosis-related neuropathic pain
• Spinal cord injury
• Post-surgical nerve damage
• Complex Regional Pain Syndrome (CRPS)

Why cannabis works well for neuropathic pain: CB1 receptors modulate aberrant nerve signalling directly in the spinal cord and brain. Multiple randomised controlled trials — including landmark studies with smoked, vaporised and oral THC:CBD preparations — show significant neuropathic pain reduction. A 2018 systematic review of 16 RCTs concluded that cannabinoids produced statistically significant pain reduction in neuropathic pain, with a number-needed-to-treat (NNT) of approximately 5–6 — comparable to many second-line neuropathic pain medications.

Inflammatory pain — strong evidence

Inflammatory pain involves immune activation driving tissue destruction and pain sensitisation. Conditions include:

• Rheumatoid arthritis and other inflammatory arthropathies
• Inflammatory bowel disease (Crohn’s disease, ulcerative colitis)
• Lupus (systemic lupus erythematosus)
• Ankylosing spondylitis
• Psoriatic arthritis

Why cannabis works: Both THC and CBD have anti-inflammatory and immunomodulatory properties. CBD has been shown to reduce TNF-α and IL-6 — pro-inflammatory cytokines central to autoimmune diseases. CB2 agonism reduces neutrophil infiltration and synovial inflammation. These are direct mechanisms of action, not just symptom management.

Clinical evidence: A 2020 survey of Australian rheumatoid arthritis patients found 24% were already using cannabis for pain management, with most reporting subjective benefit. Formal clinical trial data is growing but not yet at the level of neuropathic pain evidence.

Musculoskeletal pain — moderate evidence

The largest category of chronic pain in Australia, encompassing:

• Chronic low back pain (the most common chronic pain condition worldwide)
• Osteoarthritis — particularly hip and knee
• Fibromyalgia
• Tension headaches and cervicogenic headache

Evidence: Mostly observational and survey data. A 2021 survey of Australian medicinal cannabis patients showed significant subjective pain improvement in musculoskeletal conditions. Fibromyalgia specifically has been the subject of several small controlled trials with positive outcomes — it responds well to cannabis possibly because the ECS tone is thought to be abnormally low in fibromyalgia patients.

Cancer-related pain — strong evidence, specialised use

Cannabis is widely used in oncology and palliative care — for direct pain relief, reducing opioid requirements (“opioid-sparing”), and managing treatment side effects (nausea, neuropathy, appetite loss). The evidence base for cancer pain is substantial, supported by data on Nabiximols (Sativex) and other cannabis preparations.

Many Australian oncology units and palliative care services now have cannabis prescribers on staff or established referral pathways.

Conditions with weaker evidence

Migraines and headaches: Results are mixed. Some migraine patients report significant benefit; others find high-THC products trigger or worsen headaches, particularly with daily use. CBD may have preventive benefit through anti-inflammatory mechanisms.

Visceral pain (organ-based — IBS, endometriosis, bladder pain): Limited but emerging evidence. ECS receptors are expressed in the gut and pelvic organs; cannabis may modulate visceral hypersensitivity. Clinical trials are underway.

Acute surgical or injury pain: Cannabis is not a first-line treatment for acute severe pain. It does not provide the immediate, titratable analgesia that opioids do in acute settings.

Cannabis and the opioid crisis: the opioid-sparing effect

Australia is in the middle of a significant opioid problem. Per-capita opioid dispensing more than doubled between 2001 and 2018, and opioid-related hospitalisations have increased substantially. The harms are real: dependence, overdose (including fatal), cognitive impairment and hyperalgesia (opioid-induced increased pain sensitivity with chronic use).

Cannabis is not a direct replacement for opioids in severe or acute pain. But the opioid-sparing effect — the ability of cannabis to reduce the opioid dose needed for adequate pain control — is one of its most clinically significant properties.

The evidence from Australia: A 2021 survey of 1,800 Australian medicinal cannabis patients found:

• 36% reported reducing or stopping opioid use after starting cannabis
• 42% reported reducing other prescription pain medications
• The opioid reductions were maintained at the 12-month follow-up in the majority of cases

A 2019 US study (Reiman et al.) found that 97% of chronic pain patients who used cannabis reported being able to decrease opioid use. While survey data has limitations, the consistency of this finding across multiple countries and study designs is striking.

Mechanism: Cannabis and opioids use overlapping but distinct receptor systems. THC activates opioid-adjacent pathways without requiring activation of mu-opioid receptors — which are responsible for the respiratory depression that causes overdose and the receptor downregulation that drives opioid tolerance. Cannabis also addresses the psychological dimensions of pain (distress, catastrophisation, sleep disruption) that opioids do not.

Practical implication: If you are on regular opioid therapy for chronic pain, cannabis may allow you to maintain pain control at a lower opioid dose — reducing side effects, tolerance and dependence risk. This should always be done under medical supervision with careful monitoring and a planned taper.

Best cannabis product types for pain

Product	Onset	Duration	Best for
Flower (vaporised)	5–15 min	2–3 hours	Acute pain flares, breakthrough pain
Oil / tincture (sublingual)	15–45 min	4–6 hours	Sustained daytime or overnight relief
Capsules / edibles	60–120 min	6–8 hours	Consistent overnight coverage
Topicals (creams, balms)	15–30 min local	2–4 hours	Localised joint, muscle or skin pain
Concentrates	5–10 min	2–4 hours	Severe breakthrough pain, experienced patients

For most chronic pain patients in Australia, a combination approach is common: a long-acting oil or capsule taken morning and/or evening for baseline coverage, with a fast-acting vaporiser available for breakthrough pain flares. This mirrors the “around-the-clock + rescue analgesia” model used in opioid prescribing for pain.

A note on topicals for localised pain

CBD topicals — creams, balms and roll-ons — are sometimes underestimated. Unlike ingested cannabis, topicals are not absorbed into the bloodstream in meaningful quantities. They work locally, binding to cannabinoid receptors in skin, muscle and joint tissue. For conditions like osteoarthritis, back muscle spasm, tendonitis or joint inflammation, a quality CBD topical can provide meaningful localised relief without any systemic effects or impairment concerns. They do not require a prescription.

Concentrates for severe pain

Cannabis concentrates — live rosin, hash, wax — are high-potency products that deliver cannabinoids rapidly and at high doses. They are appropriate for patients with severe, treatment-resistant pain who have established tolerance and understand dose management. Not appropriate for new cannabis patients or those with anxiety concerns.

THC:CBD ratios for pain management

Ratio	Best for	Notes
High CBD (20:1 or more)	Inflammatory pain, daytime use, new users	Minimal psychoactive effect; safe to drive on (confirm with prescriber)
Moderate CBD (10:1 to 4:1)	Neuropathic pain, anxiety-driven pain	Mild THC effect at standard doses
Balanced (2:1 to 1:1 CBD:THC)	Neuropathic pain, sleep disruption, moderate-severe pain	Noticeable psychoactive effect; do not drive
THC-dominant (1:1 to 1:3 CBD:THC)	Severe pain, cancer pain, breakthrough episodes	More sedating; only for experienced patients under close supervision

Terpenes for pain relief

Terpenes are the aromatic compounds in cannabis that give each strain its distinctive scent — and have independent therapeutic properties relevant to pain management.

Caryophyllene — the most pain-relevant terpene. Binds CB2 receptors directly — the only non-cannabinoid known to do this — reducing neuroinflammation. Found in peppery, woody-smelling strains and oils. Also present in black pepper, cloves and cinnamon. For inflammatory pain specifically, high-caryophyllene products may be more effective.

Myrcene — the most common terpene in commercial cannabis. Acts as a muscle relaxant and analgesic, and may increase permeability of the blood-brain barrier to other cannabinoids, enhancing their effect. Earthy, musky scent. Dominant in many indica strains.

Pinene — anti-inflammatory; also partially offsets the short-term memory effect of THC. Found in piney, fresh-smelling strains. May help with inflammatory components of musculoskeletal pain.

Humulene — anti-inflammatory properties in preclinical models. Found in hops and ginger as well as cannabis. Woody, earthy, subtly spicy scent.

Linalool — primarily valuable for pain that disrupts sleep, given its sedative and anxiolytic properties. For patients whose pain is worst at night, high-linalool products may provide the best combination of analgesia and sleep improvement.

Dosing for chronic pain: a structured approach

Start low, titrate slowly. Pain patients often achieve adequate control at lower THC doses than recreational users, particularly when CBD is present. Patience is required — therapeutic dosing is not recreational dosing.

Phase 1 — CBD lead-in (weeks 1–2)

Start with CBD-only or high-CBD product: 25–50mg CBD twice daily (morning and evening). This allows your body to adapt to cannabinoid medicine and establishes a baseline from which to evaluate THC addition.

Some patients — particularly those with inflammatory pain — find significant relief at this stage and do not need THC at all. Give CBD a genuine trial before adding THC.

Expect: Mild analgesic effect beginning around 5–7 days. Anti-inflammatory effects may take 2–3 weeks to reach maximum benefit.

Phase 2 — Introduce THC cautiously (if CBD-only insufficient)

Add low THC doses: 2.5mg THC at night alongside the ongoing CBD. Preferably take the THC component in the evening to minimise daytime impairment. Increase by 2.5mg every 3–4 days until you reach adequate pain control or notice limiting side effects.

Most patients stabilise between 5–20mg THC daily. Higher doses should be under specialist supervision.

Phase 3 — Optimise and maintain

Work with your prescribing doctor to find the right combination, timing and product format. Most stable chronic pain patients end up on a split dosing schedule:

• Morning: CBD-dominant oil (minimal impairment)
• Evening: Balanced or THC-heavier oil for overnight coverage and sleep
• As needed: Fast-acting vaporiser for breakthrough pain

Pain diary: Keep a simple record of pain scores (0–10), sleep quality, and side effects. This is invaluable for working with your prescriber and demonstrates clinical response to the medication.

Managing specific pain conditions with cannabis

Fibromyalgia

Fibromyalgia is characterised by widespread musculoskeletal pain, fatigue, cognitive impairment (“fibro fog”), sleep disturbance and often mood disorders. It is one of the most cannabis-responsive chronic pain conditions, possibly because fibromyalgia patients show signs of endocannabinoid deficiency — lower levels of anandamide in cerebrospinal fluid compared to healthy controls.

Approach: CBD-dominant products twice daily, with balanced THC:CBD in the evening for sleep. Address sleep quality as a primary target — sleep improvement in fibromyalgia often produces substantial knock-on reductions in pain and fatigue.

Endometriosis

Endometriosis affects approximately 830,000 Australian women. It involves endometrial-like tissue growing outside the uterus, producing severe chronic pelvic pain, dysmenorrhoea and in some cases bowel and bladder symptoms.

CB1 and CB2 receptors are expressed in the endometrium, and preclinical research shows CBD can reduce the migration and inflammatory activity of endometrial cells. Early clinical survey data from Australia shows significant reported benefit from cannabis in endometriosis patients, particularly for pelvic pain and dysmenorrhoea.

Approach: CBD-dominant products for ongoing anti-inflammatory effects, with balanced THC:CBD for acute flares. Fast-acting vaporised low-THC flower during severe pain episodes may provide rapid symptomatic relief.

Arthritis (rheumatoid and osteoarthritis)

Both forms of arthritis respond to cannabis, through different mechanisms:

• Rheumatoid arthritis: primarily inflammatory; CBD’s immunomodulatory effects are the main mechanism. High-CBD products are most relevant.
• Osteoarthritis: primarily mechanical with secondary inflammation; CBD topicals for localised joint relief, combined with oral CBD or balanced products for systemic anti-inflammatory effect.

Topical CBD application directly to affected joints has strong anecdotal support and is increasingly being studied. It carries no systemic effects or impairment risk, making it appropriate for use during the day including while driving.

Chronic low back pain

The most common chronic pain presentation. Cannabis evidence for low back pain specifically is limited by lack of RCTs, but observational data and clinical experience suggest meaningful benefit for a significant proportion of patients.

Approach: Identify whether your back pain is primarily neuropathic (nerve involvement — burning, shooting, radiation into the leg), inflammatory (morning stiffness, responds to anti-inflammatories) or musculoskeletal (muscle tension, worse with activity). The appropriate cannabis formulation differs by pain type. Neuropathic back pain responds best to balanced THC:CBD; inflammatory back pain may respond to CBD-dominant; musculoskeletal spasm may respond to high-myrcene products combined with stretching and physiotherapy.

Cancer pain

Cannabis for cancer pain is typically managed alongside a palliative care or oncology team. Products and doses are usually higher than for other chronic pain conditions, and THC is more prominent in the formulation. The priority is maximising quality of life, which for most cancer pain patients means strong analgesic effect even at the cost of some impairment.

Cannabis also addresses cancer treatment side effects — chemotherapy-induced nausea, loss of appetite, anxiety and insomnia — simultaneously with pain, which is a significant practical advantage.

Side effects and what to monitor

Common and usually temporary (first 2–4 weeks)

• Mild dizziness or lightheadedness, particularly with initial THC doses
• Dry mouth (stays manageable with hydration)
• Increased appetite — useful for some patients, unwanted for others
• Mild sedation — generally beneficial for pain patients who need rest
• Short-term memory impairment — more pronounced with high-THC products; tends to reduce with stable dosing

Less common

• Anxiety or paranoia — more likely at high THC doses or in those prone to anxiety. Mitigated by CBD co-administration. Reduce THC dose immediately if this occurs.
• Dependence — real risk with high daily THC use, though substantially lower than with opioids. Monitor for tolerance development.
• Medication interactions — most importantly with anticoagulants, some antidepressants and anti-epileptics (CBD inhibits several CYP enzymes).

Do not drive or operate heavy machinery while impaired by THC.

THC is detectable in saliva for 12–24 hours in regular users, and roadside drug testing in Australia tests for the presence of THC (not impairment level). Discuss driving implications with your prescriber before starting any THC-containing medication. CBD-only products do not cause impairment.

Drug interactions: cannabis and common pain medications

Medication	Interaction	What to monitor
Opioids (codeine, morphine, oxycodone)	Additive CNS depression; cannabis may reduce opioid dose required	Monitor for excess sedation; work with prescriber on opioid taper
NSAIDs (ibuprofen, naproxen)	Minimal pharmacokinetic interaction; may be complementary for inflammatory pain	Monitor GI tolerance if both used regularly
Anticoagulants (warfarin)	CBD inhibits warfarin metabolism — can significantly raise warfarin blood levels	Frequent INR monitoring required; dose adjustment very likely needed
Antidepressants (SSRIs, SNRIs)	CBD inhibits CYP2D6 and CYP3A4; may raise antidepressant levels	Monitor for increased side effects; may need dose reduction
Antiepileptics (valproate, carbamazepine)	Bidirectional interactions possible; CBD raises clobazam levels	Specialist supervision required; blood level monitoring
Gabapentin/pregabalin	Additive CNS depression with THC; potential synergistic analgesic effect	Monitor for excess sedation
Muscle relaxants	Additive sedation with THC	Reduce THC dose or space timing

Always provide your complete medication list to your cannabis prescriber before starting. Do not assume a medication is safe to combine without checking.

How to get a medicinal cannabis prescription for pain in Australia

Chronic pain is the most commonly approved indication for medicinal cannabis in Australia. The process is more straightforward than many people expect.

Step 1: Telehealth consultation Book with a cannabis-specialist GP via Alternaleaf, Polln, Leafio or a similar platform. Initial consultations cost $50–150 AUD. Some platforms offer bulk-billed consultations for eligible patients.

What your prescriber needs to know:

• Your pain condition, diagnosis and how long you’ve had it
• Treatments already tried (medications, physiotherapy, procedures, surgery)
• Current medications and doses
• Functional impact of pain on your daily life and work
• Sleep quality, mood and anxiety levels
• Any history of substance use or psychiatric conditions
• Current use of opioids or other controlled medications

Step 2: Prescription issuance Most pain prescriptions are issued under the TGA’s Special Access Scheme B (SAS-B) — a streamlined process that requires no separate government approval. Your GP manages the TGA notification directly. Some GPs hold Authorised Prescriber (AP) status for specific products, allowing immediate prescribing.

Step 3: Dispensing and delivery Your prescription is filled by a TGA-registered pharmacy. Most cannabis pharmacies offer home delivery with secure, discreet packaging. Turnaround is typically 2–7 business days from prescription to delivery.

Conditions commonly approved for pain:

• Chronic non-cancer pain (most common)
• Neuropathic pain (all causes)
• Fibromyalgia
• Cancer-related pain (all stages)
• Rheumatoid arthritis and inflammatory arthropathies
• Endometriosis
• Spinal cord injury
• Complex Regional Pain Syndrome (CRPS)
• Multiple sclerosis pain
• Osteoarthritis
• Chronic low back pain (at prescriber’s discretion)

Typical ongoing cost: $150–300/month for medicinal cannabis products, depending on the formulation and dose. CBD-dominant products are less expensive than balanced or THC-dominant. Some patients with lower incomes may qualify for subsidised programs through certain prescribers.

Working with your pain specialist alongside cannabis

Cannabis is best introduced as part of, not instead of, a comprehensive pain management program. Inform all your treating practitioners — GP, pain specialist, physiotherapist, rheumatologist — that you are using or considering cannabis. Most are increasingly familiar with medicinal cannabis prescribing and can advise on interactions with their own treatments.

Physiotherapy and exercise: Cannabis’s analgesic and anti-inflammatory effects may make it easier to participate in physiotherapy and exercise programs that have long-term benefit for pain. This is a synergistic combination — cannabis addresses the acute barrier (pain preventing movement) while physiotherapy addresses the underlying cause.

Psychological pain management (CBT, ACT): Chronic pain has significant psychological dimensions. Catastrophising, fear-avoidance and pain-related depression all worsen outcomes. Psychological pain management programs — Cognitive Behavioural Therapy (CBT) and Acceptance and Commitment Therapy (ACT) — produce long-term improvements independent of medication. Cannabis may reduce pain intensity enough to engage more productively with these programs.

Pain monitoring: Use a pain diary consistently. Track daily pain scores (0–10), sleep quality, activity levels and medication taken. This creates an objective record of your cannabis treatment’s effect and helps your prescriber optimise your protocol.

Frequently asked questions

Is cannabis effective for chronic pain? For many types of chronic pain — particularly neuropathic, inflammatory and musculoskeletal — there is meaningful clinical evidence of benefit. Chronic pain is the most approved indication for medicinal cannabis in Australia. The strongest evidence is for neuropathic pain; evidence for musculoskeletal and inflammatory pain is substantial but more reliant on observational data.

Can cannabis replace my pain medication? For most patients, cannabis is added to existing management, not used instead of it. However, many patients are able to reduce opioid doses (the “opioid-sparing” effect) over time under medical supervision. Never stop or reduce prescribed pain medication without speaking to your GP.

How long does it take for cannabis to work for pain? Anti-inflammatory effects may take 2–3 weeks to peak; analgesic effects can be noticed within days. Finding the right product and dose can take 6–12 weeks of careful titration. A structured 12-week trial is typically recommended before concluding a product is ineffective.

What is the best cannabis product for back pain in Australia? Most Australian prescribers recommend starting with a balanced CBD:THC oil taken morning and evening, adding a fast-acting vaporiser for flares. The right ratio depends on your pain severity, whether it is neuropathic or musculoskeletal, sensitivity to THC and whether sleep is also affected. Browse our flower and oil range to explore available products.

Do I need a prescription for cannabis pain relief in Australia? For THC-containing products, yes. CBD topicals and low-dose oral CBD (up to 150mg/day) are available over the counter at pharmacies and may provide mild anti-inflammatory benefit. Higher-dose CBD and all THC products require a prescription from a registered GP.

Can I use cannabis for pain while on opioids? Yes, under medical supervision — and this is one of the most compelling reasons to try cannabis. Many patients are able to reduce their opioid dose when cannabis is added, which reduces dependence and overdose risk. Your prescriber and opioid-prescribing doctor should communicate and coordinate care.

Will I get addicted to cannabis? Cannabis use disorder is real and involves psychological dependence — primarily in people who use high-THC products heavily and daily over a long period. The dependence risk is significantly lower than with opioids or benzodiazepines, and CBD-dominant products carry very low dependence risk. Using cannabis for pain management with appropriate dose discipline, medical supervision and CBD co-administration substantially reduces this risk.

What cannabis products are available for pain in Australia? Browse our full range including cannabis flower for fast-acting breakthrough relief, oils and concentrates for baseline coverage and topicals for localised relief. Read our strain guide to understand which types suit different pain presentations, or learn about terpenes to understand what the aroma tells you about a product’s pharmacology.

Shop cannabis for chronic pain

Explore the most effective product formats for pain management, matched to your presentation:

• Cannabis Concentrates & CBD Oils — Full-spectrum oils and balanced THC:CBD tinctures taken morning and evening provide consistent analgesic baseline coverage. The most prescribed format for chronic neuropathic and inflammatory pain.
• Cannabis Flower — Indica & Hybrid — Vaporised for fast-acting breakthrough relief during acute flares. Indica-dominant strains with high myrcene and caryophyllene content are preferred for pain and muscle relaxation.
• CBD Topicals Australia — CBD balms and roll-ons for localised arthritis, joint pain and muscle soreness. No psychoactive effect, no prescription required for Schedule 3 products, safe for daytime use including while driving.
• Cannabis Vaporizers — Disposable pens and 510-thread cartridges deliver fast relief (10–20 minutes) for acute pain episodes. More discreet than flower and with precise dose control.
• Cannabis Edibles — Capsules — Swallowed CBD:THC capsules produce slow onset (1–2 hours) with extended effect duration — suitable for overnight pain and sleep disruption.
• Pre-Rolls Online Australia — Convenient indica pre-rolls for breakthrough pain with no preparation needed. Best used for evening and nighttime flares.

Related guides

• Cannabis for sleep Australia — Pain-related sleep disruption is the most common co-presentation
• Cannabis for anxiety Australia — Chronic pain and anxiety share overlapping ECS pathways
• Cannabis strains Australia — Indica vs hybrid vs sativa for pain management
• Terpenes cannabis guide Australia — Why myrcene and caryophyllene matter for pain relief
• THC vs CBD Australia — Choosing between CBD-dominant and balanced products for your pain type
• How to buy cannabis online Australia — Prescription to door — step-by-step guide

The bottom line

Chronic pain is the most approved and most widely prescribed indication for medicinal cannabis in Australia. The evidence base is substantial — particularly for neuropathic, inflammatory and musculoskeletal pain. Cannabis is not a cure, but for many patients it provides meaningful relief while enabling opioid reduction, better sleep and improved quality of life.

Ready to start? Browse cannabis products for pain or explore all 800+ products — with same-day delivery in Sydney, Melbourne, Brisbane, Perth, Adelaide, Gold Coast, Canberra and Darwin.